View More Recent Stories
-
Dermata Therapeutics Provides Corporate Update and Reports Second Quarter 2024 Financial Results
-
Dermata Announces Achievement of 50% Enrollment in Pivotal DMT310 Phase 3 STAR-1 Clinical Trial for Acne

